Recent Company News

• 11:08 AM ET Jun 17, 2026
  

  Johnson & Johnson CEO says focus remains on cancer, not obesity drugs - Bloomberg ($233.61, -1.57)

• 11:37 AM ET Jun 10, 2026
  

  StreetAccount ESG Research Round Up

• 10:47 AM ET Jun 09, 2026
  

  Transcript Intelligence: Structure Therapeutics at Goldman Sachs Global Healthcare Conference ($39.86, +2.08)

• 09:32 AM ET Jun 09, 2026
  

  Premarket themes include continued AI hardware rebound (9-Jun)

• 09:17 AM ET Jun 09, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:17 AM ET Jun 09, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:08 PM ET Jun 05, 2026
  

  Structure Therapeutics announces publication in Nature Medicine highlighting phase 2B ACCESS program of Aleniglipron for obesity ($37.58, 0.00)

• 01:39 PM ET Jun 03, 2026
  

  Transcript Intelligence: Structure Therapeutics at Jefferies Global Healthcare Conference ($37.04, -0.16)

• 01:39 PM ET Jun 03, 2026
  

  Transcript Intelligence : Structure Therapeutics à la conférence Jefferies Global Healthcare ($37.04, -0.16)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May